Experimental group:Recombinant L-IFN adenovirus injection

3 trials

Sponsors

Shanghai Fengxian District Central Hospital, First Affiliated Hospital of Fujian Medical University, Affiliated Cancer Hospital of Shandong First Medical University

Conditions

GBMHead and neck cancer, melanoma, cervical cancer, breast cancer, bladder cancer, ovarian cancer, lung cancersolid tumor

Phase 1

An open, single/multiple dose escalation and dose extension clinical study evaluating the safety/tolerability and initial efficacy of YSCH-01 intratumoral injection in subjects with advanced solid tumors

RecruitingChiCTR2400083915

Affiliated Cancer Hospital of Shandong First Medical Universitysolid tumor

Start: 2024-05-10Updated: 2024-05-13

Unknown Phase

Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumors: a single/multicenter, dose-increasing, cohort extension clinical study

Active, not recruitingChiCTR2200057458

Shanghai Fengxian District Central HospitalHead and neck cancer, melanoma, cervical cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer

Start: 2022-03-14Updated: 2023-10-22

An open-label, single-arm, single-center, multiple-dose, investigator-initiated clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of recombinant L-IFN adenovirus injection in the treatment of recurrent glioblastoma

Active, not recruitingChiCTR2300071543

First Affiliated Hospital of Fujian Medical UniversityGBM

Start: 2023-05-17Updated: 2023-06-12